MEDARTIS HLDG AG SF-,20

Medartis has acquired the Miami Anatomical Research Center (M.A.R.C. Institute) in Doral, Florida, establishing its first training center in the US. The institute has 36 fully equipped operating stations and room for up to 140 participants; it will continue to operate under its existing name and team. Medartis announced modernization investments but provided no financial details; the stock temporarily rose by about 1.45 percent. » More on finanzen.net

Medartis reports H1 2026 sales up 30.7% to CHF 160.8m with 17% organic growth; adjusted EBITDA rose to CHF 28.8m and adjusted net profit returned to positive at CHF 7m. The company raised its full-year guidance for organic sales growth to 17–19% and lifted the target for KeriMedical-TOUCH cases in the US to 1,800. High investments led to negative free cash flow of CHF -10m, but management expects a marked improvement in 2027/2028. The share rose 2.73% to $90.3 after the figures and profitability metrics improved significantly. » More on de.investing.com

Medartis reports group revenue of CHF 146.3m for H2 2025 and organic full-year growth of 15.7%, Core-EBITDA for H2 at CHF 26.8m and an annual margin of 18.4%. Operating free cash flow fell to CHF 9.3m after higher investments in production facilities; CAPEX was 9.6% of revenue. EMEA drove growth at 18.0%, while North America slowed to 13.4% due to sales optimizations and the replacement of a major distribution partner; five new partners are expected to fill the gap within 12 months. Medartis acquires CADskills and expects for 2026 organic core revenue growth of 16–18%, a Core-EBITDA margin in the high teens, and revenue of around CHF 322–328m with EBITDA of around CHF 52–59m, taking into account currency effects and M&A. » More on de.investing.com